Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract, with most being found in the stomach (60–70%) and small intestine (25–35%). They are histologically identified as highly cellular spindle or epithelioid cell tumours. These tumours often express c-kit (CD117 antigen), which is a major diagnostic criterion. Additional features include positivity for CD34 (60–70% of tumours), and variable expression of smooth muscle actins (20–30%) and S100 protein (10%).

Human herpesvirus type 8 DNA has been found consistently in all types of KS, in particular in CD34 positive KS tumour cells. However, the association between HHV-8 and GIST has not been investigated.

Aims: To assess the presence of HHV-8 in GISTs.

Methods: Paraffin wax embedded tissues of 86 primary GISTs and their recurrent or metastatic tumours were analysed immunohistochemically for the CD34 antigen and HHV-8 latent nuclear antigen 1 (LNA-1) and by means of the nested polymerase chain reaction (PCR) and real time PCR for HHV-8 DNA.

Results: None of the 86 GISTs contained HHV-8 DNA sequences or LNA-1 positive cells.

Conclusions: These results demonstrate the lack of HHV-8 infection in GIST tumour cells. HHV-8 does not appear to play a role in the pathogenesis of GIST, irrespective of the status of the tumour.
mouse monoclonal antibody to HHV-8 LNA-1 (NCL-HHV8LNA; clone 13B10; 1/25 dilution for 60 minutes; Novocastra Laboratories, Newcastle upon Tyne, UK). Immunostaining was performed with an OptiMax plus automated cell stainer (BioGenex, San Ramon, California, USA).

The immunohistochemistry results and the histological diagnoses were confirmed by three surgical pathologists. In total, 115 primary gastrointestinal mesenchymal tumours were identified; only those with diffuse cytoplasmic reactivity for CD117 were diagnosed as GISTs and 86 cases were used for our study. Cytoplasmic or cytoplasmic membrane staining of more than 10% of tumour cells was considered positive for CD34. For HHV-8 LNA-1, only nuclear staining was considered positive.

DNA extraction
Paraffin wax sections of the GIST samples were used for our study. DNA was prepared by means of a QIAamp tissue kit (Qiagen, Hilden, Germany). Briefly, 1.2 ml xylene was added to the paraffin wax embedded tissues (two 5 μm sections), which were then washed with ethanol. Next, genomic DNA of wax embedded tissues was obtained according to the QIAamp protocol. Only sections containing at least 85% tumour cells (no more than 15% additional non-tumour material) were used for DNA extraction.

Primers and probes
Primers and probes were used according to the method reported by Muller and colleagues15 and Stamey et al.16 For the nested PCR assay, the outer primer pair KS1 (5’-AGC CGA AAG GAT TCC ACC AT-3’) and KS2 (5’-TCC GTG TGT TCT ACG TCC AG-3’) was used to produce a 233 bp DNA fragment; the inner primer pair NS1 (5’-AGC GAT TGG ACC CCG TGT TC-3’) and NS2 (5’-AAT GAC ACA TTA GTG GTA TA-3’) was used to produce a 160 bp DNA fragment. For the real time PCR assay, forward (5’-CCA CCC TGG CAT GCA CAA C-3’) and reverse (5’-GGG TTC GGG GAT GGG AAA AGC T-3’) primers, the fluorescent Taqman probe (5’-CCA CCC AGT CAG CCC AGG CAC TAA AC-3’), and PE Applied Biosystems (Primer Express software; PE Applied Biosystems, Foster City, California, USA) were applied to amplify and detect a 49 bp amplicon in the HHV-8 minor capsid protein gene (open reading frame 25).

Nested PCR
The following conditions were used for amplification: 25 pmol of each primer, 200μg of each dNTP, 5 μl 10× PCR buffer, 1 U Taq (Promega, Southampton, UK), 1.5mM MgCl2, and 5 μl extracted DNA in a total volume of 50 μl. Reactions were carried out in a Perkin-Elmer thermocycler (Model 2400; Perkin-Elmer Cetus, Emeryville, California, USA). An initial denaturation step at 95°C for three minutes was followed by 35 cycles of 95°C for one minute, 58°C for two minutes, and 72°C for three minutes, with a final 10 minute extension at 72°C. The products of the first PCR (2 μl) were added to new reaction mixtures with the inner primer pair, and subjected to the same conditions. Products were run on a 1.5% agarose gel, stained with ethidium bromide, and viewed under ultraviolet light.

Real time PCR
TaqMan reagents and enzymes were obtained from PE Applied Biosystems. Each 25 μl PCR contained 1 x TaqMan universal PCR master mix containing uracil-N-glycosylase (AmpErase), 500nM each HHV-8 primer, 100mM HHV-8 probe, 0.2 fg of exogenous internal positive control DNA (TaqMan exogenous internal positive control), 1 x TaqMan exogenous IPC primer and probe (VIC labelled probe) mix, and 5 μl of template DNA. After a two minute incubation at 50°C for activation of the uracil-N-glycosylase, the Taq polymerase (Amplitaq Gold) was activated at 95°C for 10 minutes. Forty cycles of PCR were performed, each consisting of 95°C for 15 seconds and 60°C for one minute. Amplification was carried out in an ABI Prism 7000 sequence detection system (PE Biosystems), which permitted continuous automated reading of fluorescence intensities during PCR.

Our study was approved by the institutional review board of the Chi Mei Medical Centre.

RESULTS
Clinical data
The 86 patients were aged between 25 and 84 years (mean, 67; median, 65). The male to female ratio was 39 : 47 (1 : 1.2). Two patients had a previous history of colon adenocarcinoma and one of prostatic adenocarcinoma. At initial presentation, 82 patients had tumours limited to the primary site, two had intra-abdominal dissemination, one had liver metastasis, and one had regional lymph node metastasis.

Of the 86 patients, 49 had gastric tumours, 34 had small intestinal tumours, two had rectal tumours, and one had an oesophageal tumour.

Macroscopic observation
All tumours were well demarcated. The overlying mucosa was usually ulcerated, particularly when the tumours were larger than 5 cm in maximum diameter. The primary tumour sizes varied from 0.5 to 27 cm (mean, 7.8, 7.3, and 4.5 in the stomach, small bowel, and rectum, respectively). Nineteen tumours were larger than 10 cm, 40 were between 5 and 10 cm, and only 27 tumours were smaller than 5 cm.

Microscopic observation
Microscopically, 82 cases were of the spindle cell type and four were mixed epithelioid and spindle cell type; there were no cases of the pure epithelioid type. The mitotic counts ranged from 1 to 33 mitoses/50 high power fields (HPF). Seventy two cases had mitotic counts of no more than 5/50 HPF.

Immunohistochemical studies
The spindle cell components of all these 86 GISTs expressed CD117 diffusely and strongly; the epithelioid components of the four cases of mixed cell type showed diffuse but weaker cytoplasmic immunoreactivity for CD117. Sixty six cases of the 34 small intestinal GISTs expressed CD34, whereas all gastric, rectal, and oesophageal tumours were CD34 positive. All CD34 negative GISTs (20 cases) were located in the small intestine. All these 86 primary GISTs and their recurrent or metastatic tumours were completely negative for HHV-8 LNA-1.

Clinical follow up
After a mean follow up period of 30.2 months (median, 28.9; range, 6–112), 17 patients showed clinical malignancy. All primary tumours from these patients had a diameter of at least 5 cm (ranging from 5 to 27 cm), and six had mitotic counts more than 5/50 HPF. The numbers of clinically malignant GISTs were: nine in the small bowel, seven in the stomach, and one in the rectum. These patients showed local recurrence, liver, lung, or regional nodal metastasis, or omental dissemination. According to the four tier system of predicting the aggressiveness of GISTs suggested by Fletcher et al.,14 primary lesions were of “high risk”, four were of “intermediate risk”, and none were of “low risk” or “very low risk.” Both tumour size and mitotic activity were
significantly strong predictors of clinical malignancy in univariate analysis (t test, p < 0.005 and p < 0.05, respectively).

Molecular studies
Both nested PCR and real time PCR showed that none of these 86 primary GISTs and their recurrent or metastatic tumours contained HHV-8 DNA, regardless of tumour status, namely: site derived from, tumour size, type of cellular components they contained, mitotic activity, CD34 positivity, primary or secondary tumour, history of other cancer, and clinical malignancy.

DISCUSSION
In 2002, Fletcher et al presented a scheme of risk assessment on the basis of tumour size and mitotic count. The scheme described four risk groups, namely: high risk, intermediate risk, low risk, and very low risk groups. This scheme was useful in predicting the malignant behaviour in our primary cases. Based on this scheme, 25 of our primary cases were high risk, 34 were intermediate risk, 24 were low risk, and three were very low risk tumours. None of our 17 malignant cases. Based on this scheme, 25 of our primary cases were useful in predicting the malignant behaviour in our primary cases. In our series, the mean sizes of the malignant and benign GISTs were 13.6 and 5.7 cm, respectively, and the mitotic counts of the malignant and benign tumours were 6.6 and 2.5/50 HPF, respectively. Increases in either primary tumour size or mitotic activity were significant predictors of tumour malignancy.

‘Our results have demonstrated the lack of human herpesvirus type 8 infection in gastrointestinal stromal tumour cells, regardless of tumour status’

The CD34 expression rate of GISTs varies to some degree at different anatomical locations. Similar to that of previous studies,5 6 the CD34 expression rate in our series was 77% (66 of 86 tumours). Only 14 of the small intestinal GISTs studied here were CD34 positive, whereas those in the oesophagus, stomach, and rectum all expressed CD34.

HHV-8 is present in many disorders, including multicentric Castleman’s disease,5 6 primary effusion lymphoma,5 7 some encephalitides,8 interstitial pneumonitis in human immunodeficiency virus infected patients,9 bone marrow biopsies of human immunodeficiency virus positive patients,10 bone marrow dendritic cells from multiple myeloma,11 reactive angioendotheliomatosis,12 oral plasmablastic lymphomas in patients with AIDS,13 and all types of KS.10 11 KS is similar to GIST in three respects at least, namely: (1) KS is most frequently found in the gastrointestinal tract, although cutaneous lesions do occur; (2) KS is also composed of spindle or epithelioid cells, although erythrocytes can also be present; and (3) KSs are nearly all positive for the CD34 antigen,10 similar to GISTs.13

The relation between HHV-8 and KS has been extensively studied and discussed. HHV-8 DNA has been consistently found in all types of KS, with or without an association with AIDS.10 11 In particular, it was found in the CD34 positive spindle or epithelioid tumour cells of KS,12 13 and has been implicated as an aetiological agent in this tumour.27 28 Despite the similarities between GISTs and KSs, our results using immunostaining, nested PCR, and real time PCR have demonstrated the lack of HHV-8 infection in GIST tumour cells, regardless of tumour status. This strongly suggests that HHV-8 has no role to play in the pathogenesis of these tumours.

ACKNOWLEDGEMENTS
This study was supported by grant CMFHR9237 from the Chi-Mei Medical Centre, Tainan County, Taiwan. We thank Mr C-L Lu for his statistical assistance.

Authors’ affiliations
C C Su, Department of Pathology, Buddhist Dalin Tzu Chi General Hospital, Dain Town, Chiayi County 622, Taiwan
C F Li, Y L Liao, C N Lin, Department of Pathology, Chi-Mei Medical Centre, Tainan County, Taiwan
J J Lu, Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital and National Defence Medical Centre, Taipei

REFERENCES
PCR assay to the rescue in neurobrucellosis

Preliminary results suggesting that real time PCR assay may become the standard method for diagnosing neurological complications of brucellosis represent an important breakthrough for avoiding lasting damage to patients. It means that antibiotic treatment can be started within hours, rather than days or months it can take to reach a diagnosis by conventional means.

The other big advantage is the assay's closed, automated system, which limits the chances of cross contamination and makes it suitable for handling large numbers of specimens in a clinical laboratory—and without having to handle a class III pathogen directly.

Six patients with neurobrucellosis confirmed conventionally by a combination of clinical signs and symptoms and isolation of Brucella abortus or detection of specific agglutinins, or both, all showed specific B abortus sequences in CSF with the assay. Only four samples (66%) were positive by seroagglutination and two (33%) by direct culture. Symptoms had lasted on average 90 (range 5–365) days before diagnosis. All patients were Spanish: only one had no obvious exposure to B abortus.

Each CSF sample was tested for B abortus by culturing on isolation media, by testing for specific antibodies and testing for B abortus DNA by LightCycler real time PCR assay.

Brucellosis is endemic around the Mediterranean, in India, Mexico, Central and South America. Almost 20–40% of infections cause complications, albeit only 1–2% in the CNS, but these can be serious. Low antibiotic titres in the CSF and the low yield of culture make diagnosis difficult.